Enanta Pharmaceuticals (ENTA) Other Non-Current Assets (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Other Non-Current Assets of $3.4 million for Q1 2026, up 3512.9% on a QoQ basis from $93000.0 in Q4 2025, and little changed year-over-year from $3.4 million in Q1 2025.
Enanta Pharmaceuticals (ENTA) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Other Non-Current Assets history runs 15 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- Quarterly Other Non-Current Assets changed 0.0% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (changed 0.0% YoY) and the FY2025 annual result came in at $3.4 million, up 3474.47% from the prior year.
- Other Non-Current Assets was $3.4 million for Q1 2026 at Enanta Pharmaceuticals, up from $93000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $4.0 million in Q3 2022 and bottomed at $92000.0 in Q1 2022.
- A 5-year average of $2.1 million and a median of $3.4 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets tumbled 97.63% — and 2025, when it surged 3474.47%.
- Enanta Pharmaceuticals' Other Non-Current Assets stood at $701000.0 in 2022, then soared by 466.05% to $4.0 million in 2023, then tumbled by 97.63% to $94000.0 in 2024, then fell by 1.06% to $93000.0 in 2025, then jumped by 3512.9% to $3.4 million in 2026.
- Business Quant data shows ENTA's Other Non-Current Assets at $3.4 million in Q1 2026, $93000.0 in Q4 2025, and $3.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - | 3.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.36 Mn |
| Dec 31, 2025 | 93,000.00 |
| Sep 30, 2025 | 3.36 Mn |
| Jun 30, 2025 | 3.36 Mn |
| Mar 31, 2025 | 3.36 Mn |
| Dec 31, 2024 | 94,000.00 |
| Sep 30, 2024 | 94,000.00 |
| Jun 30, 2024 | 3.36 Mn |
| Mar 31, 2024 | 3.97 Mn |
| Dec 31, 2023 | 3.97 Mn |
| Sep 30, 2023 | 3.97 Mn |
| Jun 30, 2023 | 830,000.00 |
| Mar 31, 2023 | 696,000.00 |
| Dec 31, 2022 | 701,000.00 |
| Sep 30, 2022 | 3.97 Mn |
| Jun 30, 2022 | 703,000.00 |
| Mar 31, 2022 | 92,000.00 |
| Dec 31, 2021 | 92,000.00 |
| Sep 30, 2021 | 608,000.00 |
| Jun 30, 2021 | 608,000.00 |